Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial

Keyphrases

• Affect Responses 10%
• African American 40%
• Apolipoprotein L1 (APOL1) 100%
• Clinical Features 100%
• Clinical Trials 100%
• Collapsing Variant 10%
• Cyclosporine 20%
• Genetic Variants 10%
• Genotype P 10%
• Glomerulosclerosis 20%
• High-risk HPV 70%
• Histology 100%
• Interstitial Fibrosis 20%
• Kidney Disease 10%
• Kidney Function 10%
• Mycophenolate Mofetil 20%
• Nephropathy 100%
• Non-self 20%
• Old Age 10%
• Older Adults 10%
• Oral Dexamethasone 10%
• Primary FSGS 10%
• Proteinuria 20%
• Remission 10%
• Renal Histology 10%
• Renal Risk 10%
• Risk Allele 20%
• Risk Status 10%
• Risk Variant 10%
• Segmental Glomerulosclerosis 10%
• Self-identification 30%
• Treatment Regimen 10%
• Tubular Atrophy 10%

Medicine and Dentistry

• Allele 20%
• Apolipoprotein L1 100%
• Clinical Feature 100%
• Clinical Trial 100%
• Cyclosporine 20%
• Dexamethasone 20%
• End Stage Renal Disease 20%
• Focal Segmental Glomerulosclerosis 10%
• Glomerulosclerosis 20%
• Idiopathic Pulmonary Fibrosis 20%
• Kidney Function 10%
• Mycophenolate Mofetil 20%
• Nephropathy 100%
• Oral 10%
• Primary Outcome 10%
• Proteinuria 20%
• Pulse Rate 10%

Biochemistry, Genetics and Molecular Biology

• Allele 20%
• Apolipoprotein L1 100%
• Ciclosporin 20%
• Clinical Trial 100%
• Dexamethasone 20%
• Focal Segmental Glomerulosclerosis 10%
• Genetic Divergence 10%
• Genotyping 60%
• Kidney Function 10%
• Pulse Rate 10%